Clinical studies have shown that VEGF levels may increase by 2 to 3 times after hyperbaric oxygen therapy compared to pretreatment levels, and there is a significant positive correlation with hematoma recurrence (r = 0.68, P < .01).[22] In terms of inflammation regulation, hyperbaric oxygen therapy exhibits dose-dependent characteristics in its regulation of the immune system. This evidence concerns the gene VEGFA and hematoma.